Lidocaine Grindeks (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilizing them in an inactive state. This prevents the rapid influx of sodium ions needed for depolarization, thereby inhibiting nerve impulse generation and propagation, which results in loss of sensation and analgesia in the targeted area.

The specific dose of Lidocaine Grindeks is determined by the prescribing clinician based on the procedure, patient characteristics, and route of administration. Only a qualified health professional should set the dosage and monitor the patient during use.

Safety data for Lidocaine Grindeks in pregnancy and lactation are limited. It should be used only when clearly needed and after a risk‑benefit assessment by the treating physician. If used, the lowest effective dose should be employed, and the infant should be monitored for any adverse effects.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration of action, making it suitable for many regional techniques. Compared with bupivacaine, it has a shorter half‑life and lower cardiotoxic potential, while offering faster recovery of sensation after the procedure.

Lidocaine Grindeks should be stored below 25 °C in its original packaging, protected from moisture and direct light. The container must remain sealed until use, and any unused portion should be discarded according to local regulations after the labeled expiration date.

The product is supplied as a sterile injectable solution. It is administered by a qualified health professional either epidurally into the spinal canal, intravenously for regional limb block, or directly infiltrated into tissue for local anesthesia, following aseptic technique and appropriate dosing guidelines.

Serious risks include cardiovascular toxicity such as severe hypotension, arrhythmias, or cardiac arrest, and central nervous system toxicity manifesting as seizures or loss of consciousness. Allergic reactions ranging from rash to anaphylaxis can also occur, requiring immediate medical attention.

Patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe conduction disorders, uncontrolled heart failure, or significant hepatic impairment should avoid using Lidocaine Grindeks unless a specialist determines that benefits outweigh the risks.